Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: scopolamine Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01202188
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Early Phase 1 Interventional Results available

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

NCT02849639
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, Medication Therapy Management (MTM), Scopolamine patch
Other · Drug
Lead sponsor
Daniela Moga
Other
Eligibility
65 Years to 101 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

NCT01634139
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium low dose QD, Tiotropium high dose QD, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Results available

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

NCT00523991
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Jasper, Alabama • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

NCT00565266
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, salmeterol xinafoate, beclomethasone dipropionate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00877383
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Sep 7, 2026, 8:42 PM EDT
Terminated Phase 4 Interventional

Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study

NCT02202369
View directory record Official record
Conditions
Single Level Lumbar Decompression and Fusion Spine Surgery
Interventions
Multimodal Analgesia Treatment, Standard of Care Pain Management Protocol
Other
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Terminated Phase 2 Interventional Results available

The Antidepressant Efficacy of the Anticholinergic Scopolamine

NCT00369915
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Scopolamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Results available

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

NCT02845752
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Stiolto Respimat, Placebo Respimat
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
45 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431274
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

NCT01533935
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 7, 2026, 8:42 PM EDT
Not listed Phase 1 Interventional

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

NCT01355991
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 7, 2026, 8:42 PM EDT
Completed No phase listed Observational Results available

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol, Tiotropium Bromide/Olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01068613
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QAX028, Tiotropium, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anaheim, California • Normal, Illinois • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

NCT03673670
View directory record Official record
Conditions
COPD
Interventions
RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Winter Park, Florida • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 7, 2026, 8:42 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

NCT04272255
View directory record Official record
Conditions
Motion Sickness
Interventions
scopolamine HBr, Transdermal Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventative Delirium Protocol in Elderly Patients

NCT03541408
View directory record Official record
Conditions
Delirium
Interventions
Control, Preventative Delirium Protocol
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
65 Years to 89 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 7, 2026, 8:42 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

NCT04138758
View directory record Official record
Conditions
COPD
Interventions
Tiotropium bromide + Olodaterol, LABA/ICS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
42,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 7, 2026, 8:42 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Results available

Tiotropium In Exercise

NCT00525512
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Exercise
Interventions
tiotropium 18 mcg, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
21
States / cities
Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 7, 2026, 8:42 PM EDT
Completed No phase listed Observational

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

NCT00570544
View directory record Official record
Conditions
COPD, Emphysema
Interventions
tiotropium
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
40 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2008 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Torrance, California • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 7, 2026, 8:42 PM EDT